Adc Therapeutics Sa (ADCT)

$0.8085

+0.09

(+12.31%)

Market is closed - opens 7 PM, 26 Sep 2023

Insights on Adc Therapeutics Sa

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 18.99M → 19.28M (in $), with an average increase of 1.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -59.42M → -47.11M (in $), with an average increase of 26.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 374.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 451.5% return, outperforming this stock by 549.4%

Performance

  • $0.68
    $0.81
    $0.81
    downward going graph

    15.93%

    Downside

    Day's Volatility :15.93%

    Upside

    0.0%

    downward going graph
  • $0.70
    $5.75
    $0.81
    downward going graph

    13.58%

    Downside

    52 Weeks Volatility :87.83%

    Upside

    85.91%

    downward going graph

Returns

PeriodAdc Therapeutics SaSector (Health Care)Index (Russel 2000)
3 Months
-64.0%
-1.4%
0.0%
6 Months
-63.64%
2.2%
2.0%
1 Year
-84.55%
6.0%
5.3%
3 Years
-97.86%
26.3%
19.9%

Highlights

Market Capitalization
98.4M
Book Value
- $0.1
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.31
Wall Street Target Price
8.17
Profit Margin
-98.33%
Operating Margin TTM
-56.94%
Return On Assets TTM
-12.77%
Return On Equity TTM
-339.67%
Revenue TTM
184.4M
Revenue Per Share TTM
2.3
Quarterly Revenue Growth YOY
11.5%
Gross Profit TTM
35.1M
EBITDA
-103.9M
Diluted Eps TTM
-2.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.9
EPS Estimate Next Year
-2.61
EPS Estimate Current Quarter
-0.46
EPS Estimate Next Quarter
-0.7

Analyst Recommendation

Buy
    71%Buy
    14%Hold
    14%Sell
Based on 14 Wall street analysts offering stock ratings for Adc Therapeutics Sa(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
3
Sell
2
2
1

Analyst Forecast

What analysts predicted

Upside of 910.51%

Current $0.81
Target $8.17

Technicals Summary

Sell

Neutral

Buy

Adc Therapeutics Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adc Therapeutics Sa
Adc Therapeutics Sa
-44.19%
-63.64%
-84.55%
-97.86%
-97.57%
Moderna, Inc.
Moderna, Inc.
-10.67%
-32.6%
-16.46%
43.93%
437.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.66%
0.54%
20.22%
43.69%
111.47%
Novo Nordisk A/s
Novo Nordisk A/s
2.15%
146.19%
299.73%
451.49%
690.33%
Seagen, Inc.
Seagen, Inc.
6.95%
7.06%
57.98%
15.54%
167.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.15%
13.31%
26.28%
30.33%
91.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adc Therapeutics Sa
Adc Therapeutics Sa
NA
NA
NA
-1.9
-3.4
-0.13
0.0
-0.1
Moderna, Inc.
Moderna, Inc.
34.92
34.92
0.0
-3.42
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.9
21.9
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.86
42.86
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.48
27.48
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adc Therapeutics Sa
Adc Therapeutics Sa
Buy
$98.4M
-97.57%
NA
-98.33%
Moderna, Inc.
Moderna, Inc.
Buy
$38.1B
437.58%
34.92
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$89.4B
111.47%
21.9
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$409.3B
690.33%
42.86
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.7B
167.56%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
91.37%
27.48
35.4%

Institutional Holdings

  • Redmile Group, LLC

    16.82%
  • Citadel Advisors Llc

    4.17%
  • Prosight Management, LP

    4.04%
  • JPMorgan Chase & Co

    3.83%
  • Goldman Sachs Group Inc

    2.92%
  • Sio Capital Management, LLC

    2.68%

Corporate Announcements

  • Adc Therapeutics Sa Earnings

    Adc Therapeutics Sa’s price-to-earnings ratio stands at None

    Read More

Company Information

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.

Organization
Adc Therapeutics Sa
Employees
317
CEO
Dr. Ameet Mallik M.B.A., M.S.
Industry
Health Technology

FAQs